Nodulocystic acne: oral gugulipid versus tetracycline.
Twenty patients with nodulocystic acne were randomly allocated to one of two treatment schedules: 1) Tetracycline 500 mg or 2) Tab. Gugulipid (equivalent to 25 mg guggulsterone). Both were taken twice daily for 3 months, and both produced a progressive reduction in the lesions in the majority of patients. With tetracycline, the percentage reduction in the inflammatory lesions was 65.2% as compared to 68% with gugulipid; on comparison, this difference was statistically insignificant (P > 0.05). Follow-up at 3 months showed a relapse in 4 cases on tetracyline and 2 cases on gugulipid. An interesting observation was that the patients with oily faces responded remarkably better to gugulipid.
Thappa
D M
DM
Department of Dermatology, C.G.H.S., Bajaj Nagar, Jaipur, India.
Dogra
J
J
D000152:Acne Vulgaris / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D029744:Commiphora; D005148:Facial Dermatoses / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D010936:Plant Extracts / Q000008:administration & dosage / Q000627:therapeutic use*; D053149:Plant Gums; D012008:Recurrence; D012629:Sebum / Q000187:drug effects / Q000378:metabolism; D013752:Tetracycline / Q000008:administration & dosage / Q000627:therapeutic use*
D010936:Plant Extracts; D053149:Plant Gums; C018562:guggulu extract; D013752:Tetracycline